AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials. A ...

AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

AstraZeneca Vietnam has been honoured in the Outstanding CSR Activities category at the 2025 Top 50 Corporate Sustainability ...

Following a successful patent defense case upheld by China’s IP authority, AstraZeneca invested nearly 9 billion yuan ($1.24 billion) to establish two global R&D centres in Beijing and Shanghai, said ...

Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstraZeneca shares with a ...

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival ...

New class of Eureka Fellows selected for their outstanding efforts to build a healthier, more equitable world and will receive support to amplify their sustainability impact in Canada and around ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.